Evidence map›Paper›PMID 42410316›Full record

ArticleDiabetes, obesity & metabolism2026

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.

Simon A Berry, Iona R Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simon A BerryDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.ORCID 0009-0007-9100-8778
Iona R GoodmanDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Eleanor McNallyDepartment of Diabetes and Endocrinology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Jackie ElliottDepartment of Diabetes and Endocrinology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Ahmed IqbalDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. MATERIALS AND

methodsThis retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m

resultsParticipants (mean age 42.8 years, BMI 37.4 kg/m

conclusionsIn a real-world setting, tirzepatide significantly improves glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity with a reassuring safety profile. These findings warrant large-scale RCTs to evaluate long-term cardiovascular outcomes in this high-risk population.

Indexed as

Diabetes Mellitus, Type 1Hypoglycemic AgentsObesityTirzepatideAdultBiomarkersBlood GlucoseBody WeightCardiometabolic Risk FactorsFemaleGlycated HemoglobinHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsTirzepatideantidiabetic drugGLP‐1 analogueinsulin resistanceobesity therapyreal‐world evidencetype 1 diabetes

Identifiers

PMID42410316
PMCPMC13538728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.